ATE380868T1 - Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit - Google Patents
Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeitInfo
- Publication number
- ATE380868T1 ATE380868T1 AT02777726T AT02777726T ATE380868T1 AT E380868 T1 ATE380868 T1 AT E380868T1 AT 02777726 T AT02777726 T AT 02777726T AT 02777726 T AT02777726 T AT 02777726T AT E380868 T1 ATE380868 T1 AT E380868T1
- Authority
- AT
- Austria
- Prior art keywords
- metabolic
- fragments
- disorders
- human
- methods
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 abstract 3
- 208000037765 diseases and disorders Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000005180 public health Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32772501P | 2001-10-05 | 2001-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE380868T1 true ATE380868T1 (de) | 2007-12-15 |
Family
ID=23277766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02777726T ATE380868T1 (de) | 2001-10-05 | 2002-10-03 | Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7402393B2 (enExample) |
| EP (1) | EP1432803B1 (enExample) |
| JP (1) | JP4423038B2 (enExample) |
| AT (1) | ATE380868T1 (enExample) |
| AU (1) | AU2002339678B2 (enExample) |
| CA (1) | CA2461491A1 (enExample) |
| DE (1) | DE60224064T2 (enExample) |
| DK (1) | DK1432803T3 (enExample) |
| ES (1) | ES2295415T3 (enExample) |
| IL (2) | IL161233A0 (enExample) |
| WO (1) | WO2003050281A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478890T1 (de) | 2002-05-31 | 2010-09-15 | Serono Genetics Inst Sa | Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon |
| US8252520B2 (en) * | 2002-10-11 | 2012-08-28 | Taivex Therapeutics Corporation | Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases |
| EP1548445A3 (en) * | 2003-12-22 | 2005-11-23 | F. Hoffmann-La Roche Ag | Novel targets for obesity from fat tissue |
| US20100173829A1 (en) * | 2008-11-07 | 2010-07-08 | Aston University | Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| US9730980B2 (en) * | 2012-07-25 | 2017-08-15 | University Of Cincinnati | Method of treating type I diabetes using apolipoprotein A-IV |
| US11213567B2 (en) * | 2017-09-29 | 2022-01-04 | L&C Bio Co., Ltd. | ZAG-derived peptide and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9811465D0 (en) * | 1998-05-29 | 1998-07-29 | Tisdale Michael J | Glycoproteins having lipid mobilising properties and therapeutic applications thereof |
| WO2001051645A1 (en) * | 2000-01-14 | 2001-07-19 | Genset | Obg3 globular head and uses thereof for decreasing body mass |
| WO2003033534A2 (en) * | 2001-10-12 | 2003-04-24 | Genset S.A. | Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
-
2002
- 2002-10-03 WO PCT/IB2002/004598 patent/WO2003050281A2/en not_active Ceased
- 2002-10-03 EP EP02777726A patent/EP1432803B1/en not_active Expired - Lifetime
- 2002-10-03 AU AU2002339678A patent/AU2002339678B2/en not_active Ceased
- 2002-10-03 CA CA002461491A patent/CA2461491A1/en not_active Abandoned
- 2002-10-03 JP JP2003551302A patent/JP4423038B2/ja not_active Expired - Fee Related
- 2002-10-03 ES ES02777726T patent/ES2295415T3/es not_active Expired - Lifetime
- 2002-10-03 DE DE60224064T patent/DE60224064T2/de not_active Expired - Lifetime
- 2002-10-03 DK DK02777726T patent/DK1432803T3/da active
- 2002-10-03 AT AT02777726T patent/ATE380868T1/de active
- 2002-10-03 IL IL16123302A patent/IL161233A0/xx unknown
- 2002-10-03 US US10/491,772 patent/US7402393B2/en not_active Expired - Fee Related
-
2004
- 2004-04-01 IL IL161233A patent/IL161233A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK1432803T3 (da) | 2008-03-10 |
| IL161233A0 (en) | 2004-09-27 |
| EP1432803B1 (en) | 2007-12-12 |
| WO2003050281A3 (en) | 2003-12-04 |
| AU2002339678B8 (en) | 2003-06-23 |
| CA2461491A1 (en) | 2003-06-19 |
| DE60224064T2 (de) | 2008-11-20 |
| EP1432803A2 (en) | 2004-06-30 |
| US7402393B2 (en) | 2008-07-22 |
| DE60224064D1 (de) | 2008-01-24 |
| WO2003050281A2 (en) | 2003-06-19 |
| JP2005511088A (ja) | 2005-04-28 |
| IL161233A (en) | 2010-05-17 |
| JP4423038B2 (ja) | 2010-03-03 |
| AU2002339678A1 (en) | 2003-06-23 |
| AU2002339678B2 (en) | 2007-10-25 |
| US20070054845A1 (en) | 2007-03-08 |
| ES2295415T3 (es) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE356607T1 (de) | Verwendung von nativem zein zur verbesserung des haarzustandes und mittel | |
| DE60135439D1 (de) | Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
| ATE430193T1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
| DE602004009295D1 (de) | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie | |
| ATE207351T1 (de) | Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden | |
| ATE315390T1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| ATE380868T1 (de) | Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit | |
| ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
| ATE304854T1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| ATE480232T1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| ATE264101T1 (de) | Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose | |
| DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
| WO2003033534A3 (en) | Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| ATE498397T1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| ATE245438T1 (de) | Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis | |
| ATE466587T1 (de) | Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe | |
| WO2002066505A3 (en) | Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1432803 Country of ref document: EP |